This is the
talk page for discussing improvements to the
Mirtazapine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 60 days |
This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Mirtazapine.
|
This talk page is for
discussion on how to improve the
Mirtazapine article. If you would like to ask questions about the subject, please address them to the Reference desk. |
The contents of the California rocket fuel page were merged into Mirtazapine. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. (July 2017) |
Mirtazapine is known to cause hyponatremia in some patients and is therefore is a potential slow sodium channel blocker with cardiac symptoms typically appearing around a month after treatment, it just isn't a "fast" sodium channel blocker. This is from one of many peer reviewed journals that actually bother to include Mirtazapine in safety studies. The results on safety are questionable beyond specific cases such as general risks of overdose in people with no co-morbidities or tcas and it's cardiac safety in general is questionable compared to ssris Maiakaat ( talk) 12:12, 21 November 2023 (UTC)
This is the
talk page for discussing improvements to the
Mirtazapine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 60 days |
This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Mirtazapine.
|
This talk page is for
discussion on how to improve the
Mirtazapine article. If you would like to ask questions about the subject, please address them to the Reference desk. |
The contents of the California rocket fuel page were merged into Mirtazapine. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. (July 2017) |
Mirtazapine is known to cause hyponatremia in some patients and is therefore is a potential slow sodium channel blocker with cardiac symptoms typically appearing around a month after treatment, it just isn't a "fast" sodium channel blocker. This is from one of many peer reviewed journals that actually bother to include Mirtazapine in safety studies. The results on safety are questionable beyond specific cases such as general risks of overdose in people with no co-morbidities or tcas and it's cardiac safety in general is questionable compared to ssris Maiakaat ( talk) 12:12, 21 November 2023 (UTC)